Long-term efficacy and safety of adjunctive extended-release oxcarbazepine (Oxtellar XR® ) in adults with partial-onset seizures.

about

Long-term efficacy and safety of adjunctive extended-release oxcarbazepine (Oxtellar XR® ) in adults with partial-onset seizures.

Item

http://www.wikidata.org/entity/Q37295962

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 06 August 2015

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Long-term efficacy and safety ...... s with partial-onset seizures.

@en

Long-term efficacy and safety of adjunctive extended-release oxcarbazepine

@nl

type

Item

label

Long-term efficacy and safety ...... s with partial-onset seizures.

@en

Long-term efficacy and safety of adjunctive extended-release oxcarbazepine

@nl

prefLabel

Long-term efficacy and safety ...... s with partial-onset seizures.

@en

Long-term efficacy and safety of adjunctive extended-release oxcarbazepine

@nl

P1476

Long-term efficacy and safety ...... s with partial-onset seizures.

@en

P2093

J K Johnson

http://www.w3.org/2001/XMLSchema#string

P Baroldi

http://www.w3.org/2001/XMLSchema#string

S S Chung

http://www.w3.org/2001/XMLSchema#string

S T Brittain

http://www.w3.org/2001/XMLSchema#string

P2860

Oxcarbazepine versus carbamazepine monotherapy for partial onset seizures

Efficacy and safety of extended-release oxcarbazepine (Oxtellar XR™) as adjunctive therapy in patients with refractory partial-onset seizures: a randomized controlled trial

Pharmacokinetics and drug interactions of eslicarbazepine acetate.

What is the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs?

Comparison of the efficacy and tolerability of new antiepileptic drugs: what can we learn from long-term studies?

Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a Phase III open-label extension trial.

Perampanel, a selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307.

Long-term efficacy and safety of eslicarbazepine acetate: results of a 1-year open-label extension study in partial-onset seizures in adults with epilepsy.

Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy.

Long-term safety and efficacy of eslicarbazepine acetate as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy: results of a 1-year open-label extension study.

P31

scholarly article

P356

10.1111/ANE.12467

http://www.w3.org/2001/XMLSchema#string

P407

English

P577

2015-08-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26248506

http://www.w3.org/2001/XMLSchema#string

P932

5042072

http://www.w3.org/2001/XMLSchema#string